RATIONALE: Microvascular injury, inflammation, and coagulation play critical roles in the pathogenesis of acute lung injury (ALI). Plasma protein C levels are decreased in patients with acute lung injury and are associated with higher mortality and fewer ventilator-free days. OBJECTIVES: To test the efficacy of activated protein C (APC) as a therapy for patients with ALI. METHODS:Eligible subjects were critically ill patients who met the American/European consensus criteria for ALI. Patients with severe sepsis and an APACHE II score of 25 or more were excluded. Participants were randomized to receive APC (24 microg/kg/h for 96 h) or placebo in a double-blind fashion within 72 hours of the onset of ALI. The primary endpoint was ventilator-free days. MEASUREMENTS AND MAIN RESULTS:APC increased plasma protein C levels (P = 0.002) and decreased pulmonary dead space fraction (P = 0.02). However, there was no statistically significant difference between patients receiving placebo (n = 38) or APC (n = 37) in the number of ventilator-free days (median [25-75% interquartile range]: 19 [0-24] vs. 19 [14-22], respectively; P = 0.78) or in 60-day mortality (5/38 vs. 5/37 patients, respectively; P = 1.0). There were no differences in the number of bleeding events between the two groups. CONCLUSIONS:APC did not improve outcomes from ALI. The results of this trial do not support a large clinical trial of APC for ALI in the absence of severe sepsis and high disease severity.
RCT Entities:
RATIONALE: Microvascular injury, inflammation, and coagulation play critical roles in the pathogenesis of acute lung injury (ALI). Plasma protein C levels are decreased in patients with acute lung injury and are associated with higher mortality and fewer ventilator-free days. OBJECTIVES: To test the efficacy of activated protein C (APC) as a therapy for patients with ALI. METHODS: Eligible subjects were critically ill patients who met the American/European consensus criteria for ALI. Patients with severe sepsis and an APACHE II score of 25 or more were excluded. Participants were randomized to receive APC (24 microg/kg/h for 96 h) or placebo in a double-blind fashion within 72 hours of the onset of ALI. The primary endpoint was ventilator-free days. MEASUREMENTS AND MAIN RESULTS: APC increased plasma protein C levels (P = 0.002) and decreased pulmonary dead space fraction (P = 0.02). However, there was no statistically significant difference between patients receiving placebo (n = 38) or APC (n = 37) in the number of ventilator-free days (median [25-75% interquartile range]: 19 [0-24] vs. 19 [14-22], respectively; P = 0.78) or in 60-day mortality (5/38 vs. 5/37 patients, respectively; P = 1.0). There were no differences in the number of bleeding events between the two groups. CONCLUSIONS: APC did not improve outcomes from ALI. The results of this trial do not support a large clinical trial of APC for ALI in the absence of severe sepsis and high disease severity.
Authors: G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg Journal: Am J Respir Crit Care Med Date: 1994-03 Impact factor: 21.405
Authors: Edward Abraham; Pierre-François Laterre; Rekha Garg; Howard Levy; Deepak Talwar; Benjamin L Trzaskoma; Bruno François; Jeffrey S Guy; Martina Brückmann; Alvaro Rea-Neto; Rolf Rossaint; Dominique Perrotin; Armin Sablotzki; Nancy Arkins; Barbara G Utterback; William L Macias Journal: N Engl J Med Date: 2005-09-29 Impact factor: 91.245
Authors: Simon Nadel; Brahm Goldstein; Mark D Williams; Heidi Dalton; Mark Peters; William L Macias; Shamel A Abd-Allah; Howard Levy; Robinette Angle; Dazhe Wang; David P Sundin; Brett Giroir Journal: Lancet Date: 2007-03-10 Impact factor: 79.321
Authors: Lorraine B Ware; Michael A Matthay; Polly E Parsons; B Taylor Thompson; James L Januzzi; Mark D Eisner Journal: Crit Care Med Date: 2007-08 Impact factor: 7.598
Authors: Michael A Matthay; B Taylor Thompson; Elizabeth J Read; David H McKenna; Kathleen D Liu; Carolyn S Calfee; Jae Woo Lee Journal: Chest Date: 2010-10 Impact factor: 9.410
Authors: Chau-Chyun Sheu; Michelle N Gong; Rihong Zhai; Feng Chen; Ednan K Bajwa; Peter F Clardy; Diana C Gallagher; B Taylor Thompson; David C Christiani Journal: Chest Date: 2010-05-27 Impact factor: 9.410
Authors: Kathleen D Liu; Joseph Levitt; Hanjing Zhuo; Richard H Kallet; Sandra Brady; Jay Steingrub; Mark Tidswell; Mark D Siegel; Graciela Soto; Michael W Peterson; Mark S Chesnutt; Charles Phillips; Ann Weinacker; B Taylor Thompson; Mark D Eisner; Michael A Matthay Journal: Am J Respir Crit Care Med Date: 2008-06-19 Impact factor: 21.405
Authors: Jorrit J Hofstra; Alexander D Cornet; Bart F de Rooy; Alexander P Vlaar; Tom van der Poll; Marcel Levi; Sebastian Aj Zaat; Marcus J Schultz Journal: Crit Care Date: 2009-09-09 Impact factor: 9.097